AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04021771 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational Curriculum Intervention
Description: The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.
Study NCT01970397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVEDERM® Ultra XC
Description: Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
Study NCT01970397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero Balance®
Description: Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
Study NCT00816855 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel, cisplatin, fluorouracil
Description: neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly
Study NCT03481387 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aortic Valve Replacement with Perceval S sutureless heart valve
Description: Patients will be treated with the PERCEVAL S heart valve (PERCEVAL S valve) which is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
Study NCT02629328 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CardioCel
Description: Treatment with CardioCel implant
Study NCT04504461 — intervention group
Intervention type: OTHER
Intervention: Analysis of feasibility and costs
Description: Analyze the feasibility and costs of performing laparoscopic inguinal hernioplasty in an ambulatory surgery center
Study NCT03118076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine and 50 μg dexmedetomidine
Description: Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
Study NCT03118076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Nerve blocks were administered with 0.3% ropivacaine.
Study NCT04132648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Oral supplement one time at 2,000 mg
Study NCT04132648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral supplement one time at 2,000 mg
Study NCT02894489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: corneal lenses
Description: wear corneal lenses on daily basis
Study NCT02894489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: large diameter lenses
Study NCT02673723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docozine
Description: dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
Study NCT02673723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The same amount of saline is given for 10 seconds after surface anesthesia
Study NCT01781871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar13
Description: Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.
Study NCT01781871 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax
Description: 0.5ml Pneumovax injected intramuscularly at day 1.
Study NCT04491240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXO 1 inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
Study NCT04491240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXO 2 inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
Study NCT04491240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation
Description: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
Study NCT02234557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: 6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.~Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Practice will consist of warm up, followed by practice of selected pieces of the form.~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention).
Study NCT02091921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
Study NCT02103881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 500 mg of intramuscular ketamine for severe pre-hospital agitation
Study NCT02103881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Haloperidol 10 mg intramuscular for severe prehospital agitation.
Study NCT04041141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT Scan
Description: An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)
Study NCT04041141 — intervention group
Intervention type: DEVICE
Intervention: Experimental Oral Stent Device
Description: Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place
Study NCT03058848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU Start
Description: PKU Start is a powdered, phenylalanine-free, infant formula, containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and long chain polyunsaturated fatty acids (LCPs); Arachidonic acid (AA) and Docosahexaenoic acid (DHA). It is suitable for use from birth.~The recommended amount of the product for each participant will be determined and prescribed by a dietitian.
Study NCT04698512 — intervention group
Intervention type: DEVICE
Intervention: AVFistuloplasty with Sirolimus coated balloon
Description: After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon
Study NCT01477138 — intervention group
Intervention type: PROCEDURE
Intervention: pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)
Description: Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
Study NCT05735613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteotome crestal sinus lifting
Description: Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. The drills can be sequentially used to widen the osteotomy site to the same level (1 mm short of the sinus floor), an osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level, the osteotome will be tapped gently to fracture up the sinus floor.Clinical check for membrane still intact, blocking the patient's nostrils and asking the patient to blow through his or her nose. Xenograft will be added as the grafting material and pushed to the sinus through the osteotomy site until the desired height of sinus elevation will be gained, the implant fixture will be inserted. Smart peg will be placed on implant and Ostell will be used to record ISQ.
Study NCT05735613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osseodensification crestal sinus lifting
Description: Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. Change the drill motor to reverse-densifying Mode (counterclockwise drill speed 800-1500 rpm with copious irrigation), Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor, use the next wider Densah Bur (3.0mm) in the same mode and advance it into the previously created osteotomy with modulating pressure and a pumping motion. When feeling the haptic feedback of the drill reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments, the next wider densah drills advance in the osteotomy.Clinical check for membrane still intact. Xenograft added and pushed to the sinus through the osteotomy site then the implant fixture will be inserted.
Study NCT05735613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piezoelectric crestal sinus lifting
Description: initial osteotomy will be performed with a 2-mm twist drill to remove the cortical bone, then the intralift tips (Intralift; TKW1, TKW2, TKW3,TKW4, TKW5; Satelec). TKW1 to TKW4 tips have diameters of 1.35 mm, 2.1 mm, 2.35 mm, and 2.8 mm and will be used to gradually widen the access canal to the Schneider membrane, gentle pressure will be applied on the tips to deepen the pathway, and a sterile spray (80 mL/min) cooling the tips to avoid heat injury. The TKW5 tip will be then inserted into the access canal, and the ultrasonic activation for 5 seconds with internal irrigation of 40 mL/min and repeated at 50 mL/min and then 60 mL/min. The sinus membrane will be pushed upward by the hydraulic pressure, the floating of the sinus membrane will be evaluated, and then the TKW4 (Ø 2.8 mm) will be used again to widen the access canal to the sinus membrane before plugging the bone graft.xenograft added. Implant fixture inserted and flap statured
Study NCT04559087 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic Surgery
Description: NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall.
Study NCT04559087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Description: NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall.
Study NCT03443895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEF0117 oral capsule
Description: 0.6, 2 and 6mg of AEF0117
Study NCT01309932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052 (NS5A Inhibitor)
Description: Tablets, Oral, 60 mg, Once daily, 24 weeks
Study NCT04858113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blephaclean
Description: Blephaclean wipes are used to help treat symptoms of blepharitis (eyelid inflammation) which is commonly associated with dry eye disease and meibomian gland dysfunction.
Study NCT04858113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Baby Shampoo
Description: Conventional baby shampoo
Study NCT04570306 — intervention group
Intervention type: DRUG
Intervention: Belimumab
Description: The study will involve 80 adult patients diagnosed with SLE who will be started on belimumab (standard approved dose of i.v. 10 mg/kg or subcutaneous 200 mg/week) due to active disease. The intention to start belimumab will be made by the treating Rheumatologist(s), in accordance to the current standard of care, and on the basis of shared physician-patient decision making.
Study NCT00119197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: killed whole cell oral cholera vaccine
Description: Bivalent oral killed cholera vaccine: each dose of this vaccine contains:~* Inactivated V.Cholerae Inaba (569B), Classical biotype - 25.109 cells~* Inactivated V.Cholerae Ogawa (Cairo 50) Classical biotype - 25.109 cells~* Inactivated V.Cholerae Inaba (Phil 6973) El Tor biotype - 50.109 cells~* Inactivated V.Cholerae O139 - 50.109 cells~each 1.5 mL dose given orally, two doses given 14 days apart
Study NCT00119197 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Heat Killed E. coli
Description: Escherichia coli K12 strain placebo: each dose of placebo contains heat-killed E. coli K12 strain in an amount whose optical turbidity is identical to that for the cholera vaccine.~Each 1.5 mL dose given orally, two doses given 14 days apart
Study NCT03067402 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years
Study NCT03067402 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nuclear Perfusion Imaging Stress Test
Description: Patient receives routine nuclear image perfusion stress test
Study NCT01109186 — intervention group
Intervention type: OTHER
Intervention: biological parameters
Description: blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
Study NCT00836394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galileo (whole body vibration (WBV) therapy)
Description: 6 minutes of training on 5 days a week for 3 months
Study NCT00412191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
Study NCT03011749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLT PET/CT
Description: FLT PET/CT before first series of Radium-223 and after 2 series
Study NCT03443895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo capsule
Study NCT00367432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
Study NCT01376362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1b
Description: Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
Study NCT03723980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: it is a natural product obtained from beehive. it has been evaluated for biocompatibility and toxicity; and it is found that it is extremely biocompatible material. In our study, propolis powder will be mixed with saline in a ratio of 1 : 1.5 (propolis powder(wt) / saline(vol)) to form paste; and inserted into the root canals. it will be inserted once and will remain in root canals for 4 days.
Study NCT03723980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
Study NCT03228862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol 40000, 60000 and 80000 once weekly
Study NCT00347932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-403
Description: Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
Study NCT00347932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
Study NCT01724216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse sequences
Description: Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
Study NCT00504439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-656933-AAA
Description: The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
Study NCT02407912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: ciplatin in distilled water is injected into the chest for 48 h.
Study NCT03351478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.
Study NCT03351478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.
Study NCT03351478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
Study NCT03351478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
Study NCT03351478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
Study NCT02581124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951
Study NCT02581124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Study NCT00471003 — intervention group
Intervention type: DRUG
Intervention: Pritor (Telmisartan , BAY68-9291)
Description: Primary care hypertensive patients starting the therapy with Telmisartan
Study NCT01291849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dixon up-and-down method
Description: The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml-1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
Study NCT02969538 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Total etching time
Description: Apply 35% phosphoric acid on dentin and enamel by 15 seconds.
Study NCT02969538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half-reduced etching time
Description: Apply 35% phosphoric acid on enamel by 15 seconds and dentin by 7 seconds.
Study NCT01001364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Budesonide
Description: formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
Study NCT01001364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foraseq
Description: formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
Study NCT00504439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: SB-656933-AAA matching placebo tablets will be administered orally.
Study NCT00504439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin will be provided as a 40 mg tablet.